Gene Scissors Moving Beyond Double-Strand Break Limits: Advanced Base Editing Opens Path for Precision Treatment of Diabetes and Genetic Diseases
Background
CRISPR-Cas9, derived from bacterial adaptive immunity, has established itself as a game-changing tool in genome editing research. It demonstrates the convenience of precisely controlling target genes solely by recognizing a specific sequence through the binding of single-guide RNA (sgRNA) and the Cas9 enzyme. However, early technologies faced significant safety barriers for clinical application. A representative limitation is that the Cas9 enzyme induces double-stranded DNA breaks (DSBs) by cleaving both strands of the target DNA.
Cells activate the non-homologous end joining (NHEJ) pathway during DSB repair. This process can lead to unintended base deletions or random insertions, posing a persistent risk of large-scale chromosomal deletions. Additionally, off-target effects—where unintended cleavage occurs at sequences similar to the target—are cited as obstacles to clinical translation. The genome regions that could be corrected were also limited by the protospacer adjacent motif (PAM) constraint. The lack of technology to safely deliver correction materials to target tissues in vivo was also a major factor delaying commercialization.
Key Discoveries
Researchers have integrated multi-faceted protein engineering strategies to overcome these limitations. Leading approaches include discovering new Cas orthologs from bacterial populations and creating high-fidelity Cas9 variants through redesigned protein structures. These variant enzymes have successfully significantly reduced off-target effects by inhibiting binding to non-target sequences. By relaxing PAM constraints, the editable genomic regions have been dramatically expanded. Additionally, chemically improved and stabilized sgRNAs have played a key role in increasing the efficiency of Cas9-sgRNA complex formation and target binding affinity.
A turning point that changed the paradigm of genome editing was the emergence of next-generation platforms that do not induce DSBs. Base editors, which combine a Cas9 nickase (with inhibited cutting function) with a deaminase enzyme, precisely substitute single bases without DNA cleavage. Prime editors, which incorporate reverse transcriptase, have enabled the insertion and deletion of desired sequences without causing DNA damage. This has established a foundation for safely correcting point mutations, which account for many genetic diseases, while blocking the risk of chromosomal translocation.
In vivo delivery technology has also advanced rapidly. Lipid nanoparticles (LNP) and ribonucleoprotein (RNP) electroporation have become standard platforms. LNP delivery to non-hematopoietic tissues and ex vivo RNP electroporation have achieved high editing yields. This has led to proven long-term clinical efficacy in patients with sickle cell disease, β-thalassemia, and cystic fibrosis. This background has also driven achievements in identifying insulin secretion pathways and developing immune-evasive artificial islet cell lines in diabetes research.
Significance and Outlook
The advancements in gene-editing technology summarized here mark a turning point, shifting the disease treatment paradigm from simple symptom alleviation to the permanent correction of causative genes. It has laid the academic foundation to expand targets from single-gene defects to complex metabolic diseases like diabetes. We have entered an era of precise restoration, moving away from destroying defective genes toward repairing damaged bases back to their normal sequences.
Behind the rosy outlook, challenges remain to be solved in clinical settings. The in vivo LNP delivery yield to non-hematopoietic tissues requires further improvement to ensure stable efficacy. The immune rejection response triggered by the human immune system to bacterial-derived Cas proteins is also a challenge to overcome. Analysis suggests that the problem of high drug pricing in mass production processes and the strict validation criteria of regulatory agencies are also variables that determine the speed of commercialization.
The CRISPR-Cas9 system has revolutionized modern life sciences, driving a paradigm shift in biomedical research and becoming an indispensable tool in molecular biology due to its remarkable precision, efficiency, and simplicity. Originating from a bacterial adaptive immune mechanism, CRISPR-Cas9 has evolved rapidly, providing a versatile framework for manipulating genetic material and addressing a wide spectrum of human diseases. Recent progress includes the discovery of novel Cas orthologs and the rational engineering of Cas9 variants to enhance editing fidelity, broaden target range, and minimize off-target effects. Structural and functional optimization of single-guide RNAs (sgRNAs) has further improved target binding affinity, stability, and Cas9-sgRNA complex formation, thereby increasing overall editing performance. The development of high-fidelity Cas9 derivatives and next-generation platforms such as base editors and prime editors has enabled precise single-nucleotide substitutions and small insertions or deletions without generating double-stranded DNA breaks. Advanced delivery systems-including viral vectors, lipid nanoparticles, and ribonucleoprotein electroporation-have facilitated efficient CRISPR-mediated editing across in vitro, ex vivo, and in vivo models. Remarkable therapeutic milestones have been achieved in treating monogenic disorders such as sickle cell disease, β-thalassemia, and cystic fibrosis, where long-term clinical benefits have been documented. Furthermore, CRISPR-Cas9 technology is redefining diabetes research by enabling precise modeling of disease mechanisms, uncovering molecular pathways involved in glucose homeostasis, and opening new avenues for cellular and gene-based therapies. This review highlights recent advances in CRISPR-Cas9-mediated genome editing, emphasizing breakthroughs in primary cell editing and the development of translational models for genetic diseases and diabetes mellitus.
This research provides practical guidelines for the clinical development and production processes of treatments for rare genetic diseases and chronic metabolic diseases. The ex vivo therapy, which extracts blood cells, precisely edits them with RNPs, and re-infuses them into patients, has already demonstrated the curative potential of a single dose in clinical stages. The development of inhalable, tissue-specific LNP formulations targeting airway epithelial cells in cystic fibrosis patients or pancreatic tissue in diabetes patients is emerging as a key next-generation pipeline for major pharmaceutical companies. In the field of diabetes, research is active in applying gene editing to stem cell-derived pancreatic beta cells to remove human leukocyte antigens (HLA) that trigger immune rejection. It is evaluated as a catalyst that will accelerate the commercialization of universal 'off-the-shelf' diabetes cell therapies, overcoming the limitations of existing islet transplantation which suffers from donor shortages.